Mostrar el registro sencillo del ítem

Artículo

dc.creatorMajem, M.es
dc.creatorManzano, J. L.es
dc.creatorMarquez-Rodas, I.es
dc.creatorMujika, K.es
dc.creatorMuñoz-Couselo, E.es
dc.creatorPérez-Ruiz, E.es
dc.creatorCruz Merino, Luis de laes
dc.creatorEspinosa, E.es
dc.creatorGonzalez-Cao, M.es
dc.creatorBerrocal, A.es
dc.date.accessioned2022-10-10T13:32:37Z
dc.date.available2022-10-10T13:32:37Z
dc.date.issued2021
dc.identifier.citationMajem, M., Manzano, J.L., Marquez-Rodas, I., Mujika, K., Muñoz-Couselo, E., Pérez-Ruiz, E.,...,Berrocal, A. (2021). SEOM clinical guideline for the management of cutaneous melanoma (2020). Clinical and Translational Oncology, 23 (5), 948-960. https://doi.org/10.1007/s12094-020-02539-9.
dc.identifier.issn1699-048Xes
dc.identifier.urihttps://hdl.handle.net/11441/137761
dc.description.abstractMelanoma afects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage≥III. Stage I–III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immuno‑ therapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.es
dc.formatapplication/pdfes
dc.format.extent13 p.es
dc.language.isoenges
dc.publisherSpringer Naturees
dc.relation.ispartofClinical and Translational Oncology, 23 (5), 948-960.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectMelanomaes
dc.subjectAdjuvant treatment metastatic treatmentes
dc.subjectStaginges
dc.titleSEOM clinical guideline for the management of cutaneous melanoma (2020)es
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.publisherversionhttps://link.springer.com/article/10.1007/s12094-020-02539-9es
dc.identifier.doi10.1007/s12094-020-02539-9es
dc.journaltitleClinical and Translational Oncologyes
dc.publication.volumen23es
dc.publication.issue5es
dc.publication.initialPage948es
dc.publication.endPage960es

FicherosTamañoFormatoVerDescripción
SEOM clinical...pdf822.0KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional